Bruker 

$65.8
45
-$1.66-2.46% 今天

統計

當日最高
67.01
當日最低
65.3
52週最高
94.86
52週最低
53.79
成交量
1,041,242
平均成交量
1,098,785
市值
10.17B
市盈率
28.11
股息收益率
0.3%
股息
0.2

即將到來

股息

0.3%股息收益率
10年增長
N/A
5年增長率
4.56%
3年增長率
7.72%
1年增長率
N/A

收益

31Oct預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
0.47
0.56
0.65
0.74
預期每股收益
0.615867
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 BRKR 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

75.4$平均價格目標
最高估價為 $90。
來自過去 6 個月內的 6 個評級。這不是投資建議。
買入
33%
持有
50%
賣出
17%

關於

Health Technology
Medical Specialties
Manufacturing
Analytical Laboratory Instrument Manufacturing
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Show more...
首席執行官
Frank Laukien
員工
9707
國家
US
ISIN
US1167941087

上市公司